Sacubitril with valsartan
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Sacubitril with valsartan and local guidelines before prescribing.
Angiotensin receptor-neprilysin inhibitor
Mechanism
Neprilysin inhibitor plus angiotensin receptor blocker.
Uses
Heart failure with reduced ejection fraction.
Dosing
- Sacubitril/valsartan | 24/26 mg or 49/51 mg twice daily initially; target 97/103 mg twice daily.
Cardiology: Heart Failure - Sacubitril/valsartan | HFrEF: 24/26 mg or 49/51 mg twice daily, titrated to 97/103 mg twice daily; stop ACE inhibitor at least 36 hours before.
Cardiology: Cardiomyopathies
Side effects
Hypotension, hyperkalaemia, renal impairment, angioedema.
Interactions
Never with ACE inhibitors (36-hour wash-out); potassium-sparing diuretics.
Contraindications and cautions
ACE inhibitor use, angioedema, pregnancy
Monitoring
U&E, BP
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce start dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Stop ACE inhibitor 36 hours before starting; check U&E.
More from the textbook: uses, cautions and other points
- Sacubitril/valsartan raises BNP (it blocks its breakdown) - use NT-proBNP to monitor.
Cardiology Investigations - NICE treatment approach : Offer all four classes to eligible patients with HFrEF. Do not necessarily wait for one drug to reach maximum dose before introducing another class. Choose the sequence and starting doses according to blood pressure, renal function, potassium, frailty and clinical stability. If symptoms persist despite maximally …
Cardiology: Heart Failure - Natriuretic peptides (ANP, BNP) - released by stretched atria and ventricles; promote sodium and water loss and vasodilatation; broken down by neprilysin (blocked by sacubitril).
Cardiology: Anatomy Physiology and Pharmacology - Natriuretic peptides rise (counter-regulatory; measured as BNP and NT-proBNP) → sacubitril boosts them.
Cardiology: Anatomy Physiology and Pharmacology - Sacubitril/valsartan | ARNI for HFrEF; 36-hour gap after ACE inhibitor.
Cardiology: Anatomy Physiology and Pharmacology - Switch ramipril to sacubitril/valsartan (36 hours after the last ACE inhibitor dose) - blocks RAAS and boosts natriuretic peptides.
Cardiology: Anatomy Physiology and Pharmacology - Full heart failure therapy for reduced EF: ACE inhibitor/ARB or sacubitril/valsartan, beta blocker, MRA and SGLT2 inhibitor, plus diuretics for congestion.
Cardiology: Ischaemic Heart Disease (ACS) - Optimise heart failure therapy first: ACE inhibitor or sacubitril/valsartan, beta blocker, MRA, SGLT2 inhibitor, and diuretics.
Cardiology: Valvular heart disease
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (4 mentions)
- Cardiology Investigations (1 mention)
- Cardiology: Ischaemic Heart Disease (ACS) (1 mention)
- Cardiology: Valvular heart disease (1 mention)
- Cardiology: Heart Failure (8 mentions)
- Cardiology: Cardiomyopathies (4 mentions)
- Respiratory: Emergencies (1 mention)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Emergencies (1 mention)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (1 mention)
- ENT: Emergencies (1 mention)
- Clinical Immunology: Allergy, anaphylaxis, urticaria and angioedema (1 mention)
- Integrated cardiology chapter (15 mentions)
- Integrated respiratory chapter (1 mention)